Among male patients (hazard ratio [ HR ] = 1.666, P = 0.004), larger tumor diameter ( HR = 2.643, P < 0.001), high
tumor stage ( HR = 1.874, P < 0.001), high tumor grade ( HR = 1.645, P = 0.004), lymph node metastasis ( HR = 2.910, P < 0.001), and high pretreatment NLR ( HR = 2.240, P < 0.001) were significantly associated with poor CSS in univariate analysis [Figure 2].
Stages of tumor:
Tumor stage 2 was found to be higher 23 (39.7%) followed by
tumor stage 3 in 17 (29.3%), stage 4 in 11 (19%) while stage 1 tumor was found in 7 (12.1%) patients.
Clinicopathological parameters in our study involved patients' age, gender, tumor size, lymph node metastasis, tumor grade, and
tumor stage. miR-204 level was significantly associated with no lymph node metastasis (P = 0.003) and early
tumor stages (stages I-II; P = 0.048).
Use of at least view the wall of the digestive tract and organs in the vicinity of tumor assessments walls of the digestive tract, determination of
tumor stage affecting organs adjacent to the digestive tube, for removing tissue, for drainage and collection of fluid into the gastrointestinal tract for drainage of bile ducts in the stomach or duodenum, classic trasabdominln ultrasonography and ultrasound addition, under the control and targeted biopsy of liver tumors.
Clinical data (gender, age, tumor location, and
tumor stage) were obtained from medical records.
In our previous report, we identified a -31C/G polymorphism located within the CDE/CHR repressor binding site, which was found to be associated with
tumor stage and grade in UCs [12].
(1,2) Before the implementation of targeted therapies, LN metastases were considered to be a portent of markedly decreased survival, regardless of the
tumor stage. (3,4) However, the role of lymphadenectomy and the relative benefit of retroperitoneal LN dissection in the context of modern adjunctive therapies have not been conclusively addressed in the clinical literature, and there are only limited studies available in the pathologic literature.
The most important determinant of survival in ovarian carcinoma cases is
tumor stage. Most patients presenting with disease confined to the ovaries (stage 1) can be cured, with a 5-year survival rate of >90% (1).
The BRCA1 and BRCA2 mutation carriers in this study did not differ in regard to
tumor stage, grade, or histology.
In addition, the analysis of the PTEN gene and the loss of PTEN function was predictive of patient survival outcome at a statistically significant level after adjusting for
tumor stage (p-value = 0.009), suggesting that PTEN status provides additional prognostic information not otherwise available to physicians.
Other factors that appeared to be associated with a poor prognosis were (1) older age, (2) a primary tumor location in a paranasal sinus, (3) an advanced
tumor stage, (4) an external approach to surgery, and (5) the absence of adjuvant radiotherapy.
Although ROMA was significantly more sensitive in other comparisons based on
tumor stage, Dr.
